Blame drug 'middlemen' for Ozempic and Wegovy prices, Novo Nordisk CEO tells Congress
CEO Lars Fruergaard Jørgensen will shift the blame for the high prices of the company’s popular weight loss treatments to drug middlemen and the ‘complex’ U.S. health care system today during a committee hearing in Congress.
Novo Nordisk, Denmark
O faturamento da farmacêutica dinamarquesa Novo Nordisk com o Ozempic e o Wegovy é tanto que as vendas acumuladas logo ...
Ahead of a Senate hearing centered on high prices for Novo Nordisk’s in-demand semaglutide medications, lawmakers are ...
On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 ...
Hi, it’s Bob in New York. I’ve been writing about drug costs for years, and Ozempic and Wegovy turn out to be in a unique ...
Financial giants have made a conspicuous bullish move on Novo Nordisk. Our analysis of options history for Novo Nordisk NVO revealed 10 unusual trades. Delving into the details, we found 70% of ...
Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental ...
The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.
Novo Nordisk A/S’s obesity shot Wegovy also prevents strokes, heart attacks and death. The price of those benefits is far ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback